Acupuncture Combined With Sphenopalatine Ganglion Needling for Allergic Rhinitis: A Randomized Controlled Trial
International Forum of Allergy & Rhinology · 2026-04 · 16 (4) · 380-390
DOI: 10.1002/alr.70085 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 16.12.2025. Verfasst von Shanshan Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Acupuncture Therapy, Rhinitis, Allergic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
Background
Although the therapeutic effects of acupuncture and sphenopalatine ganglion (SPG) needling for allergic rhinitis (AR) are well established, evidence for the efficacy of their combination remains limited.
Methods
In this multicenter, randomized, parallel‐controlled trial, 260 patients with persistent moderate‐to‐severe AR were assigned to 8 weeks of pharmacotherapy (MED; loratadine 10 mg/day), acupuncture (ACU; 3 sessions/week), sphenopalatine ganglion needling (SPG‐N; 1 session/week), or combination therapy (COM, which received both acupuncture and SPG needling). The primary outcome was the response rate (≥30% reduction in total nasal symptom score [TNSS]) at Week 8. Secondary outcomes included changes in TNSS, total non‐nasal symptom score (TNNSS), rhinoconjunctivitis quality of life questionnaire (RQLQ), and visual analogue scale (VAS) scores from baseline to Weeks 2, 4, 8, and the 4‐week follow‐up.
Results
At Week 8, response rates differed significantly among groups (COM: 82.54%; ACU: 71.43%; SPG‐N: 55.74%; MED: 45.31%; p < 0.001) and were sustained at the 4‐week follow‐up. The COM showed the earliest significant improvement at Week 2 (63.49%, p < 0.001). Compared to MED, both COM (relative risk [RR] = 1.90, 95% confidence interval [CI], 1.40‐2.58; p < 0.001) and ACU (RR = 1.61, 95% CI, 1.18–2.21; p = 0.003) were associated with significantly higher response rates at Week 8, whereas SPG‐N was not (RR = 1.27, 95% CI, 0.90–1.79; p = 0.17).
Conclusion
This study demonstrated that acupuncture combined with SPG needling provides more rapid, robust, and sustained symptomatic improvement in AR, offering an evidence‐based non‐pharmacologic alternative for AR management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
- National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- Kunshan Hospital of Chinese Medicine, Kunshan, China.
- Yancheng Hospital of Traditional Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, Yancheng, China.
ORCID-Profile: Shanshan Liu, Yongjun Peng
Zitieren
APA
Liu, S., Shen, Y., Meng, X., Huang, X., Yang, C., Zhang, S., Zeng, C., Wang, X., & Peng, Y. (2026). Acupuncture Combined With Sphenopalatine Ganglion Needling for Allergic Rhinitis: A Randomized Controlled Trial. International Forum of Allergy & Rhinology, 16(4), 380-390. https://doi.org/10.1002/alr.70085
Vancouver
Liu S, Shen Y, Meng X, Huang X, Yang C, Zhang S, et al. Acupuncture Combined With Sphenopalatine Ganglion Needling for Allergic Rhinitis: A Randomized Controlled Trial. International Forum of Allergy & Rhinology. 2026;16(4):380-390. doi:10.1002/alr.70085
BibTeX
@article{Liu2026,
author = {Liu, Shanshan and Shen, Yan and Meng, Xin and Huang, Xinlei and Yang, Chen and Zhang, Siyao and Zeng, Chunli and Wang, Xiaoxiao and Peng, Yongjun},
title = {Acupuncture Combined With Sphenopalatine Ganglion Needling for Allergic Rhinitis: A Randomized Controlled Trial},
journal = {International Forum of Allergy & Rhinology},
year = {2026},
volume = {16},
number = {4},
pages = {380--390},
doi = {10.1002/alr.70085}
}
EUVIMED